Investor Relations

Revance Therapeutics is an emerging Silicon Valley biotechnology leader developing neuromodulators for the treatment of aesthetic and therapeutic conditions. Revance uses a unique proprietary, stabilizing excipient peptide technology to create novel, differentiated therapies. The company’s lead compound, DaxibotulinumtoxinA for Injection (RT002), is in clinical development for a broad range of aesthetic and therapeutic indications, including glabellar lines, cervical dystonia, plantar fasciitis, upper limb spasticity and chronic migraine. RT002 has the potential to be the first long-acting neuromodulator. The company is advancing a robust pipeline of injectable and topical formulations of DaxibotulinumtoxinA.

on

Copyright West LLC. Minimum 15 minutes delayed.

 

INVESTOR RELATIONS CONTACTS
Jeanie D. Herbert
Sr. Director, Investor Relations
714-325-3584
jherbert@revance.com


Burns McClellan
Ami Bavishi
212-213-0006
abavishi@burnsmc.com

Revance Therapeutics, Inc.
P.O. Box 303
Newark, California 94560-0303
Phone: (510) 742-3400
Fax: (510) 742-3401

Transfer Agent
Computershare
USA
+1 (877) 373 6374
(US, Canada, Puerto Rico)
+1 (781) 575 3120 (non-US)
web.queries@computershare.com

Shareholder Correspondence should
be mailed to:
Computershare
P.O. Box 505000
Louisville, KY  40233
 
Shareholder Overnight
correspondence should be sent to:
Computershare
462 South 4th Street, Suite 1600
Louisville, KY 40202

 

Shareholder Tools Request Printed Materials Request Email Alerts Download Library RSS News Feeds Share this Page Search Investor Site
Shareholder Tools